Journal ArticleDOI
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
Edward Abraham,Antonio Anzueto,Guillermo Gutierrez,Sidney Tessler,Gerry San Pedro,Richard G. Wunderink,Anthony R. Dal Nogare,Stanley A. Nasraway,Steve Berman,Robert N. Cooney,Howard Levy,Robert P. Baughman,Mark J. Rumbak,R. Bruce Light,Lona Poole,Randy Allred,John Constant,James E Pennington,Steven B. Porter +18 more
TLDR
It was found there was no association between therapy with TNFα MAb and increased rapidity in reversal of initial shock or prevention of subsequent shock, and baseline plasma interleukin-6 concentrations were not associated with improvement in survival after TNF α MAb therapy.About:
This article is published in The Lancet.The article was published on 1998-03-28. It has received 647 citations till now. The article focuses on the topics: Septic shock & Intensive care.read more
Citations
More filters
Journal ArticleDOI
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok Junhee Seok,Shaw Warren,G. Cuenca Alex,N. Mindrinos Michael,V. Baker Henry,Weihong Xu,Daniel R. Richards,Grace P. McDonald-Smith,Hong Gao,Laura Hennessy,Celeste C. Finnerty,Cecilia M Lopez,Shari Honari,Ernest E. Moore,Joseph P. Minei,Joseph Cuschieri,Paul E. Bankey,Jeffrey L. Johnson,Jason L. Sperry,Avery B. Nathens,Timothy R. Billiar,Michael West,Marc G. Jeschke,Matthew B. Klein,Richard L. Gamelli,Nicole S. Gibran,Bernard H. Brownstein,Carol L. Miller-Graziano,Steve E. Calvano,Philip H. Mason,J. Perren Cobb,Laurence G. Rahme,Stephen F. Lowry,Ronald V. Maier,Lyle L. Moldawer,David N. Herndon,Ronald W. Davis,Wenzhong Xiao,Wenzhong Xiao,Ronald G. Tompkins +39 more
TL;DR: This study shows that, although acute inflammatory stresses from different etiologies result in highly similar genomic responses in humans, the responses in corresponding mouse models correlate poorly with the human conditions and also, one another.
Journal ArticleDOI
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis.
Hong Wang,Hong Liao,Mahendar Ochani,Marilou Justiniani,Xinchun Lin,Lihong Yang,Yousef Al-Abed,Haichao Wang,Christine N. Metz,Edmund J Miller,Kevin J. Tracey,Luis Ulloa +11 more
TL;DR: The authors showed that nicotine attenuates serum HMGB1 levels and improves survival in experimental models of sepsis, even when treatment is started after the onset of the disease and suggest that selective nicotinic agonists for the α7nAChR might have therapeutic potential for the treatment of septicemia.
Journal ArticleDOI
The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome
TL;DR: The goals of this article are to provide an overview of sepsis and its complications, discuss the role of the endothelium in orchestrating the host response insepsis, and emphasize the potential value of the artery as a target for sepsi therapy.
Journal ArticleDOI
Sepsis and septic shock
Richard S. Hotchkiss,Lyle L. Moldawer,Steven M. Opal,Konrad Reinhart,Isaiah R. Turnbull,Jean Louis Vincent +5 more
TL;DR: With earlier recognition and more compliance to best practices, sepsis has become less of an immediate life-threatening disorder and more of a long-term chronic critical illness, often associated with prolonged inflammation, immune suppression, organ injury and lean tissue wasting.
Journal ArticleDOI
Acute renal failure: definitions, diagnosis, pathogenesis, and therapy
TL;DR: The epidemiology and pathophysiology of ARF are discussed, including the vascular, tubular, and inflammatory perturbations and implications for potential future therapies to decrease the high mortality.
References
More filters
Journal ArticleDOI
APACHE II: a severity of disease classification system.
TL;DR: The form and validation results of APACHE II, a severity of disease classification system that uses a point score based upon initial values of 12 routine physiologic measurements, age, and previous health status, are presented.
Journal ArticleDOI
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
Kevin J. Tracey,Kevin J. Tracey,Yuman Fong,David G. Hesse,Kirk R. Manogue,Annette T. Lee,George C. Kuo,Stephen F. Lowry,Anthony Cerami +8 more
TL;DR: Protection against shock, vital organ dysfunction, persistent stress hormone release and death was conferred by administration of antibodies 2 h before bacterial infusion, indicating that cachectin is a mediator of fatal bacteraemic shock and suggesting that antibodies against Cachectin offer a potential therapy of life-threatening infection.
Journal ArticleDOI
The Natural History of the Systemic Inflammatory Response Syndrome (SIRS): A Prospective Study
TL;DR: This prospective epidemiologic study of SIRS and related conditions provides the first evidence of a clinical progression from SirS to sepsis to severe sepsi and septic shock, and stepwise increases in mortality rates in the hierarchy.
Journal ArticleDOI
Detection of circulating tumor necrosis factor after endotoxin administration.
Hamish R. Michie,Kirk R. Manogue,David R. Spriggs,Arthur Revhaug,S. T. O'Dwyer,Charles A. Dinarello,Anthony Cerami,Sheldon M. Wolff,Douglas W. Wilmore +8 more
TL;DR: It is concluded that the response to endotoxin is associated with a brief pulse of circulating tumor necrosis factor and that the resultant responses are effected through the cyclooxygenase pathway.
Journal ArticleDOI
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Elizabeth J. Ziegler,Charles J. Fisher,Charles L. Sprung,Richard C. Straube,Jerald C. Sadoff,Garrett E. Foulke,CH Wortel,Fink Mp,Dellinger Rp,Nelson N.H. Teng +9 more
TL;DR: A randomized, double-blind trial in patients with sepsis and a presumed diagnosis of gram-negative infection was conducted in this article, where the patients received either a single 100mg intravenous dose of HA-1A or placebo.